Amarin Plummets After Patent Appeal Shows Key Drug Sales at Risk

(Bloomberg) -- Amarin Corp. fell the most since March after it faced tough questioning from a U.S. appeals court reviewing the validity of patents on its only product, the heart treatment Vascepa.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.